Nonsteroidal anti‐inflammatory drugs for primary dysmenorrhoea
Information
- DOI:
- https://doi.org/10.1002/14651858.CD001751Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 20 October 2003see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Gynaecology and Fertility Group
- Copyright:
-
- Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
Jane Marjoribanks: Took the lead in writing the review, performed independent data extraction and quality assessment of the included trials, was responsible for statistical analysis and interpretation of the data.
Michelle Proctor: Took the lead in writing the protocol, performed independent data extraction and quality assessment of the included trials, was responsible for statistical analysis and interpretation of the data.
Cindy Farquhar: Initiated and conceptualised the review, commented on drafts of the protocol and review.
Sources of support
Internal sources
-
University of Auckland, School of Medicine, Auckland, New Zealand.
External sources
-
Princess of Wales Memorial Trust Fund administered by the Mercia Barnes Fund, New Zealand.
Declarations of interest
None known
Acknowledgements
To Valeria Ivanova and Owen Sinclair who advised on the early stages of the review, to Will Stones who commented on the final draft and to all the people who kindly translated trials free of charge.
Version history
| Published | Title | Stage | Authors | Version |
| 2015 Jul 30 | Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea | Review | Jane Marjoribanks, Reuben Olugbenga Ayeleke, Cindy Farquhar, Michelle Proctor | |
| 2010 Jan 20 | Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea | Review | Jane Marjoribanks, Michelle Proctor, Cindy Farquhar, Roos S Derks | |
| 2003 Oct 20 | Nonsteroidal anti‐inflammatory drugs for primary dysmenorrhoea | Review | Jane Marjoribanks, Michelle Proctor, Cindy Farquhar, Ussanee S Sangkomkamhang, Roos S Derks | |
Differences between protocol and review
The following criteria represent changes or additions to the original protocol for this review:
1) The original protocol specified an intended limit to the interventions to be considered, i.e. the four major NSAIDs prescribed for dysmenorrhoea (naproxen, ibuprofen, indomethacin, mefenamic acid) and two commonly used non‐opioid analgesics (aspirin, paracetamol). However while searching was being carried out it became clear that a much wider group of NSAIDs are now commonly used and also that aspirin is itself commonly considered a NSAID, so it was decided to make the review more comprehensive in its evaluation by considering all types of NSAIDs, including aspirin, versus other NSAIDs, paracetamol or placebo.
2) It was decided to include only double blinded trials, and to exclude trials which analysed fewer than 80% of randomised participants, on grounds of quality.
3) Trials with participants who used intrauterine contraception (IUCD) were excluded unless the results for this group were analysed separately, on the grounds that dysmenorrhoea related to IUCD use is secondary rather than primary (Ylikorkala 1978).
4) Where trials compared differing doses of the same NSAID against placebo or another drug, the results were pooled where feasible, or (in the case of crossover trials where results could not be pooled) the highest recommended dose was used for the purpose of comparison. See Characteristics of Included Studies for details.
5) Cyclooxygenase‐2 inhibitors (Cox 2 inhibitors), such as praecox and celecoxib, were excluded as they will be considered in a separate review.
